Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Furui Subsidiary Receives US Approval for Liver Testing Device

publication date: Apr 16, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Echosens™ has been given FDA 510(k) approval to market its FibroScan® device in the US. Echosens, a French company, is wholly owned by Inner Mongolia Furui Medical Science Co. FibroScan is a noninvasive device that tests for liver fibrosis. It uses an ultrasound machine and a technology called transient elastography. The device has been marketed in Europe since 2003; the US is the last major country to approve FibroScan. More details....

Stock Symbol: (SHE: 300049)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors